T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
Guru Sonpavde,Cora N. Sternberg,Yohann Loriot,Aurélien Marabelle,Jae-Lyun Lee,Aude Flechon,Guilhem Roubaud,Damien Pouessel,Vittorina Zagonel,Fabio Calabrò,Giuseppe Luigi Banna,Sang Joon Shin,Francisco E. Vera-Badillo,Thomas Powles,Eva Hellmis,Paulo A.P. Miranda,Ana Rita Lima,Ugochi Emeribe,Sun Min Oh,Sebastien J. Hotte +19 more
TL;DR: In this paper , the authors evaluated the safety and efficacy of fixed-dose durvalumab at a more convenient dosing schedule in a previously treated patient population, more similar to a real-world clinical setting.
Journal ArticleDOI
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study
Andrea Necchi,Gregory R. Pond,Marc C. Smaldone,Sumanta K. Pal,Kevin Chan,Yu-Ning Wong,Rosalia Viterbo,Guru Sonpavde,Lauren C. Harshman,Simon J. Crabb,Ajjai Alva,Simon Chowdhury,Ugo De Giorgi,Sandy Srinivas,Neeraj Agarwal,Aristotelis Bamias,Jack Baniel,Ali Reza Golshayan,Sylvain Ladoire,Cora N. Sternberg,Linda Cerbone,Evan Y. Yu,Joaquim Bellmunt,Ulka N. Vaishampayan,Günter Niegisch,Syed A. Hussain,Daniel W. Bowles,Rafael Morales-Barrera,Matthew I. Milowsky,Christine Theodore,Dominik Berthold,Srikala S. Sridhar,Thomas Powles,Jonathan E. Rosenberg,Matthew D. Galsky +34 more
TL;DR: No differences in efficacy outcomes or ability to deliver adjuvant chemotherapy were observed between RARC and ORC, suggesting that the increasing use of RARC is justifiable from an oncological viewpoint.
Journal ArticleDOI
A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC).
Bernard Escudier,David Cella,Jürgen E. Gschwend,Thomas Powles,Cora N. Sternberg,R. Hodge,M. Lau,Maureen P. Neary,Faisal Mehmud,Timothy Eisen +9 more
TL;DR: This study evaluates whether tolerability in pazopanib vs. sunitinib in treatment naive mRCC patients (pts) is a legitimate and useful endpoint for cancer therapy, and shows an association between toxicity/intolerability and a response on HRQoL.
Journal ArticleDOI
857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
Petros Grivas,Elizabeth R. Plimack,Arjun Vasant Balar,Daniel Castellano,Peter H. O'Donnell,Joaquim Bellmunt,Thomas Powles,Noah M. Hahn,R. de Wit,Dean F. Bajorin,Misoo C. Ellison,Tara L. Frenkl,Stephen Michael Keefe,Jacqueline Vuky +13 more
TL;DR: The author states that he holds stock in Halozyme Therapeutics, and that the speaker’s Bureau, which represents Bristol-Myers Squib, Medivation, Genentech and Gilead, have declared no conflicts of interest.
Journal ArticleDOI
Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).
Thomas Powles,Robert J. Motzer,Bernard Escudier,Sumanta K. Pal,Christian K. Kollmannsberger,Joanna Pikiel,Howard Gurney,Sun Young Rha,Se Hoon Park,Poul F. Geertsen,Marine Gross-Goupil,Enrique Grande,Cristina Suarez,Alan Arroyo,Mark Dean,Daniel J. George,Toni K. Choueiri +16 more
TL;DR: Optimizing the sequence of systemic therapy to improve outcomes in patients with advanced RCC remains a clinical challenge and TKI, a tyrosine kinase inhibitor, was recently introduced.